While the monotherapy did not reach significant inhibition, the combination of LAS194046 0.1 nM and fluticasone propionate 1 nM reached significant inhibition of LPS-induced IL-8 and MPP9 release in peripheral blood neutrophils from severe asthma and COPD patients (Fig. 4A) as well as in neutrophils from sputum of COPD patients (Fig. 4B). This evidence concerns the gene CXCL8 and chronic obstructive pulmonary disease.